BioSpace News Archive

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, will be presenting five posters on Bylvay (odevixibat) at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) meeting being held December 12–18.

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that on December 1, 2021 the Company entered into a strategic cooperation agreement and associated ancillary agreements (the “Agreements”) with Kitanihon Pharmaceutical Co., Ltd. (“KP”).

Ampio Pharmaceuticals, Inc. announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 25,000,000 shares of the Company’s common stock and warrants to purchase 15,000,000 shares of the Company’s common stock at a combined purchase price of $0.90 per Share in a registered direct offering.

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX),today announced it had signed a non-binding letter of intent (“LOI”) to acquire a company focused on developing Point-of-Care diagnostics for early detection of diseases including cancers and SARS-CoV-2 (COVID-19) through a range of non-invasive and affordable point of care and at-home/in-office test kits.

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced new preclinical data demonstrating the potential of CPI-818, the company’s ITK inhibitor, for the prevention and therapy of acute graft versus host disease in patients receiving allogeneic hematopoietic cell transplantation.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced new data from a Phase 1 study of GBT021601 (GBT601).

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), today presents long-term follow-up data from its Phase 1/2 B-AMAZE dose-finding trial of FLT180a for the treatment of hemophilia B at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.

Less than two months after the first breakthrough surgery, NYU Langone Health has performed its second successful investigational xenotransplantation procedure using a genetically engineered pig kidney.

Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today it has completed its acquisition of Hillrom.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), announced today new and updated results from the CARTITUDE clinical development program studying ciltacabtagene autoleucel (cilta-cel) in the treatment of multiple myeloma, which were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.